Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Operating Expenses for 10 consecutive years, with $216.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 58.38% year-over-year to $216.4 million; the trailing twelve-month figure through Jun 2026 stood at $740.6 million (up 41.1% YoY), and the FY2025 full-year result was $600.3 million, up 28.04% from the prior year.
• Operating Expenses rose to $216.4 million in Q2 2026 per KNSA's latest filing, from $185.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $216.4 million in Q2 2026 and bottomed at $46.3 million in Q2 2022.
• Historically, Operating Expenses has averaged $109.8 million across 5 years, with a median of $102.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses decreased 3.98% in 2022, then surged 70.24% in 2024.
• Over 5 years, Operating Expenses stood at $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then jumped by 70.24% to $141.8 million in 2024, then advanced by 28.57% to $182.4 million in 2025, then grew by 18.67% to $216.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $216.4 million, $185.0 million, and $182.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.